{"id":"W4247747570","doi":"10.2165/00128413-200514910-00054","title":"Omalizumab [Xolair; Novartis] has been launched in Canada for the treatment of moderate-to-severe, persistent asthma","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Omalizumab; Medicine; Asthma; Mepolizumab; Launched; Pharmacy; Family medicine; Internal medicine; Immunology; Immunoglobulin E","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006119711,0.0003719834,0.0007749733,0.0004428717,0.001365603,0.001019512,0.0006532898,0.0009050627,0.01335655],"category_scores_gemma":[0.0007861014,0.000142253,0.000498073,0.0004208993,0.0005467635,0.0002257557,0.0004147973,0.001778607,0.003251434],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.003734437,"about_ca_system_score_gemma":0.00785938,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1811917,"about_ca_topic_score_gemma":0.4272883,"domain_scores_codex":[0.9995622,0.00005119509,0.00002311874,0.00004221753,0.0001684681,0.0001527555],"domain_scores_gemma":[0.9991516,0.00008339445,0.00008392462,0.00002671313,0.0002778821,0.0003764247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008774928,0.001254741,0.01665441,0.001304596,0.0002816844,0.002670625,0.000112657,0.0005090987,0.0425899,0.003737722,0.2492932,0.6728165],"study_design_scores_gemma":[0.00461455,0.004119565,0.09775645,0.0004552141,0.0005308807,0.005228591,0.0001561525,0.001491991,0.02148959,0.0007666084,0.8632975,0.00009298742],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.2638929,0.2428318,0.006261136,0.06374234,0.01067536,0.00157232,0.009314443,0.003244733,0.398465],"genre_scores_gemma":[0.6969832,0.05386128,0.01139162,0.02203284,0.002321816,0.0001752259,0.008530878,0.000253131,0.20445],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.8188083,"threshold_uncertainty_score":0.3602742,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03356341046701216,"score_gpt":0.2764187798871618,"score_spread":0.2428553694201497,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}